We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Radius (RDUS) Enrols First Patient in Breast Cancer Study
Read MoreHide Full Article
Radius Health, Inc. (RDUS - Free Report) announced that the first patient has been enroled in the phase I study on pipeline candidate, RAD140.
RAD140 is a nonsteroidal selective androgen receptor modulator (SARM) which is being evaluated for the treatment of hormone receptor positive breast cancer. The phase I trial is a safety and dose-ranging study in approximately 40 patients suffering from progressive metastatic or locally advanced or metastatic breast cancer. Postmenopausal women with metastatic hormone receptor positive breast cancer will receive escalating doses of RAD140 by oral administration over a period of 28 days in part A of the study. The primary safety outcomes include rate of dose-limiting toxicities, adverse events related to treatment and tolerability as measured by dose interruptions or adjustments. In addition, pharmacokinetics, pharmacodynamics and tumor response will also be evaluated.
The SARM mechanism of action is differentiated from both selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs). Consequently, RAD140 has significant potential to complement future applications of elacestrant (RAD1901) by targeting distinct mechanisms of endocrine resistance.
We note that an investigational new drug application submitted to the FDA for RAD140 has been accepted.
Radius’ share price has increased 1.4% year to date compared with the industry’s4.6% gain.
In April the FDA approved Tymlos (abaloparatide-SC) for the treatment of postmenopausal women with high risk osteoporosis for fracture — defined as history of osteoporotic fracture — multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapies. Although the osteoporosis market in the United States holds great promise as approximately 1.4 million postmenopausal women suffer osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's (LLY - Free Report) Forteo and Amgen Inc's (AMGN - Free Report) Prolia. Moreover, the approved label carries a boxed warning of osteosarcoma (a malignant bone tumor). The company, however, suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues.
Meanwhile, Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women.
Aduro Biotech’s loss per share estimates narrowed from $1.46 to $1.29 for 2017 and from $1.41 to $1.26 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Radius (RDUS) Enrols First Patient in Breast Cancer Study
Radius Health, Inc. (RDUS - Free Report) announced that the first patient has been enroled in the phase I study on pipeline candidate, RAD140.
RAD140 is a nonsteroidal selective androgen receptor modulator (SARM) which is being evaluated for the treatment of hormone receptor positive breast cancer. The phase I trial is a safety and dose-ranging study in approximately 40 patients suffering from progressive metastatic or locally advanced or metastatic breast cancer. Postmenopausal women with metastatic hormone receptor positive breast cancer will receive escalating doses of RAD140 by oral administration over a period of 28 days in part A of the study. The primary safety outcomes include rate of dose-limiting toxicities, adverse events related to treatment and tolerability as measured by dose interruptions or adjustments. In addition, pharmacokinetics, pharmacodynamics and tumor response will also be evaluated.
The SARM mechanism of action is differentiated from both selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs). Consequently, RAD140 has significant potential to complement future applications of elacestrant (RAD1901) by targeting distinct mechanisms of endocrine resistance.
We note that an investigational new drug application submitted to the FDA for RAD140 has been accepted.
Radius’ share price has increased 1.4% year to date compared with the industry’s 4.6% gain.
In April the FDA approved Tymlos (abaloparatide-SC) for the treatment of postmenopausal women with high risk osteoporosis for fracture — defined as history of osteoporotic fracture — multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapies. Although the osteoporosis market in the United States holds great promise as approximately 1.4 million postmenopausal women suffer osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's (LLY - Free Report) Forteo and Amgen Inc's (AMGN - Free Report) Prolia. Moreover, the approved label carries a boxed warning of osteosarcoma (a malignant bone tumor). The company, however, suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues.
Meanwhile, Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women.
Zacks Rank & Key Pick
Radius Health currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Aduro Biotech , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aduro Biotech’s loss per share estimates narrowed from $1.46 to $1.29 for 2017 and from $1.41 to $1.26 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>